SMART IMM_LOGO NEW.png
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
May 02, 2024 06:00 ET | Smart Immune
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial PARIS, France, May 2, 2024 – Smart Immune, a clinical-stage biotechnology company developing...
Tevogen Logo Notified.png
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
May 01, 2024 08:05 ET | Tevogen Bio Inc
For full year 2023, the operating expenses for Tevogen Bio Inc were $8.8 million.
YPrime CNS Survey - Key eCOA Attributes
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET | Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
barinthuslogo.jpg
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
May 01, 2024 07:00 ET | Barinthus Biotherapeutics
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.
TessellateBio+-+logo+without+brand+promise.png
Tessellate BIO Announces Appointment of Professor Sandra Strauss to Scientific Advisory Board
May 01, 2024 04:00 ET | Tessellate Bio
AMSTERDAM and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment...
Beacon Biosignals, Inc.
Beacon Biosignals and Takeda Launch Strategic Collaboration to Advance Neurobiomarkers and Endpoints for Sleep Disorders
April 30, 2024 09:00 ET | Beacon Biosignals
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals, the leader in at-home EEG and computational neurodiagnostics, announced a collaboration with Takeda to conduct at-home sleep monitoring...
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
April 30, 2024 09:00 ET | Kamari Pharma
NESS ZIONA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic...
Fractyl-Logo.png
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
April 30, 2024 08:38 ET | Fractyl Health, Inc.
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Replay_Logo_Black_CMYK.png
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
April 30, 2024 07:00 ET | Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies Phase 1/2...
ViaNautis.png
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors
April 30, 2024 07:00 ET | ViaNautis Bio
ViaNautis Bio appoints Dr Steven M. Altschuler as Chairman of its Board of Directors Co-Founder of Spark Therapeutics with over 20 years of industry experience to support ViaNautis Bio in its next...